Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Hologic CE marks Pap slide imaging system

This article was originally published in Clinica

Executive Summary

Hologic has CE marked its ThinPrep integrated imager for sale in Europe to aid in the diagnosis of cervical cancer. The device is designed to analyse ThinPrep Pap test slide in around 90 seconds, during which time each cell and cell cluster is scanned. Using optical density analysis, the system identifies diagnostically-relevant cells or cell groups and presents the resulting data to the cytotechnologist for interpretation. If no abnormalities are identified, the slide can be marked as negative or put through the laboratory's quality control system. A complete slide review is required if any suspicious cells are detected; this dual review process combines human interpretative expertise with the power of computer imaging, claims Bedford, Massachusetts-based Hologic.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT044383

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel